BJT-778 antibody therapy shows early promise in Hep D trial
Bluejay Therapeutics’ investigational antibody therapy BJT-778 appears to safely and effectively lower levels of the hepatitis D virus (HDV) and markers of liver inflammation…
Hepatitis
Tobevibart, elebsiran can suppress hepatitis D virus: Phase 2 data
Vir Biotechnology’s investigational therapy tobevibart, used alone or in combination with another company candidate called elebsiran, can reduce hepatitis D virus (HDV) levels and…
Hepatitis C test-and-treat program works for migrants in Italy: Study
A test-and-treat strategy was effective at identifying and treating hepatitis C among migrants and refugees in Italy coming from low-income countries where the condition…
FDA breakthrough designation granted to larsucosterol for AH
The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to larsucosterol, Durect’s investigational therapy for people with severe alcohol-associated hepatitis…
Autoimmune hepatitis treatment zetomipzomib trial seeks patients
A Phase 2a clinical trial testing Kezar Life Sciences’ investigational therapy zetomipzomib in adults with autoimmune hepatitis who did not respond well to standard…
Chronic hepatitis B undertreated globally, real-world study finds
Global rates for evaluating chronic hepatitis B and starting appropriate treatment are lower than they should be, especially among women and Asian minorities living…
Hepatitis Awareness Month promotes screening, vaccination
Throughout May, the U.S. Centers for Disease Control and Prevention (CDC) will work with public health partners to raise awareness of viral hepatitis…
Gilead awards $4M funding to hepatitis B, C, D elimination projects
Gilead Sciences has awarded $4 million in funding via its ALL4LIVER grant program to organizations worldwide whose community-based efforts will help the World Health…
Canada unlikely to hit 2030 hepatitis C elimination target: Study
Current screening and treatment strategies won’t allow Canada to eliminate new cases of hepatitis C by 2030, a population modeling study found. That’s the…
WHO: Despite advances in care, deaths from hepatitis increasing
Technologies to prevent, detect, and treat viral hepatitis have advanced considerably in recent decades, but the number of people dying from these infections continues…
